Lexicon Pharmaceuticals,
Inc. LXRX, a biopharmaceutical company focused on discovering and
developing breakthrough treatments for human disease, announced today that it
has received "Fast Track" status from the U.S. Food and Drug Administration
(FDA) for the development of LX1033, an orally-delivered small molecule drug
candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).
"We are pleased with the FDA's grant of Fast Track status for LX1033 in IBS-d,
recognizing this important area of unmet medical need and the potential
benefits that LX1033 could provide for those suffering from this disease,"
said Pablo Lapuerta, M.D., senior vice president and chief medical officer at
Lexicon.
LX1033, an inhibitor of tryptophan hydroxylase (TPH) that acts locally in the
gastrointestinal tract, is currently being evaluated in a Phase 2 clinical
trial for IBS-d. The Phase 2 trial is a randomized, double-blind study
designed to evaluate the safety and efficacy of LX1033 versus placebo in
approximately 360 IBS-d patients, with results expected in the first half of
2013. LX1033 is a follow-on compound to LX1031, a previous-generation oral,
locally-acting TPH inhibitor developed by Lexicon which had previously shown
clinical benefit in a Phase 2 trial for IBS-d. Results from the LX1031 Phase 2
trial have been published in the journal Gastroenterology (2011; 141:507-516).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in